Delhi has reported H1N1 cases at a rising pace, with 138 new infections recorded in the past 24 hours. The fresh cases have taken the city's 2026 H1N1 tally to 2,446. The latest rise has prompted the Delhi government to review hospital preparedness.
Recent regulatory decisions show companies expanding access to innovative medicines while pursuing new markets and indications
Researchers at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) have developed a smartphone-based tool for Alzheimer’s detection
Piramal Alternatives has invested Rs 215 crore in Kolors Healthcare as India’s wellness market sees rising demand for preventive and personalized healthcare. The investment will support Kolors’ expansion, infrastructure upgrades...
Cancer care gets a new boost in Japan as Biocon Biologics secures marketing approval for its pegfilgrastim biosimilar. The approval expands Biocon’s oncology portfolio and strengthens its presence in Japan’s biosimilar market
Dr Reddy’s Laboratories has secured a key approval for its arthritis treatment portfolio in India. The company received marketing approval for its abatacept biosimilar from the Central Drugs Standard Control Organisation (CDSCO).
H1N1 cases have crossed 2,300 in Delhi, prompting hospitals to strengthen testing and preparedness. The capital has recorded 2,308 H1N1 cases so far in 2026. Total Influenza A and B cases have crossed around 3,000.
The US weight-loss drug market faces a new affordability challenge as employers reconsider coverage for GLP-1 medicines amid rising healthcare costs
Air pollution is emerging as a significant contributor to the global cancer burden. As the latest research places fine particulate matter at the center of the concern
Palm Bioactives are gaining attention in NCD research. Scientists are exploring whether naturally occurring palm compounds can help address non-communicable diseases
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")